Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Scientific Officer | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,477 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-22 · Grant · Acquired 7,866 · Balance 31,149 F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Row 2 · 2026-01-22 · Grant · Acquired 3,328 · Balance 34,477 F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2012 Filed May 29, 2012 20:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-12-031025 · doc4.xml · derivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2022-05-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 05/24/2012. Read SEC document |
| July 31, 2004 Filed Aug 1, 2014 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $90.86 | $72,688.00 |
DisclosureSEC source: 0001209191-14-049983 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $90.86 (range $90.33 to $91.24). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.